Literature DB >> 20599224

Complications after pancreatectomy for neuroendocrine tumors: a national study.

Jillian K Smith1, Sing Chau Ng, Joshua S Hill, Jessica P Simons, Edward J Arous, Shimul A Shah, Jennifer F Tseng, Theodore P McDade.   

Abstract

BACKGROUND: Although resection of pancreatic neuroendocrine tumors (PNETs) has a demonstrated survival advantage, further evaluation of the overall morbidity of these procedures is needed. Our objective was to examine a composite outcome of major postoperative complications, including in-hospital mortality.
MATERIALS AND METHODS: The Nationwide Inpatient Sample (NIS), 1998-2006, was used to identify all patients with a diagnosis of PNET who had undergone pancreatectomy. Candidate predictors consisted of patient and hospital characteristics. Univariate analyses included chi(2) tests. Multivariate analyses were performed with logistic regression to determine which predictors were independently associated with the composite outcome.
RESULTS: A total of 463 (2274 nationally weighted) patients were identified. Overall composite postoperative complication rate was 29.6%. The majority of complications involved infections (11.1%), digestive complications (8.8%), or pulmonary compromise (7.3%). In-hospital mortality rate was 1.7%. High Charlson comorbidity score, procedure type of Whipple or total pancreatectomy, and urban hospital location were all associated with significantly increased complication rate. Logistic regression analysis demonstrated: Charlson score of > or =3 versus score of 0 (adjusted odds ratio (OR) 4.1, 95% confidence interval (CI) 2.1-8.3), surgery type of Whipple or total pancreatectomy versus partial pancreatectomy (adjusted OR 2.7, 95% CI 1.8-4.1), and hospital location of urban versus rural (adjusted OR 4.5, 95% CI 3.0-6.9).
CONCLUSIONS: While in-hospital mortality rates are low for surgical resection of PNETs, there is a considerable overall postoperative complication rate associated with these procedures. Careful patient and surgery selection may be the key to a surgical treatment approach for PNETs that may optimize outcomes. Copyright 2010 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2010        PMID: 20599224     DOI: 10.1016/j.jss.2010.04.017

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  16 in total

1.  Resection of Primary Gastrointestinal Neuroendocrine Tumor Among Patients with Non-Resected Metastases Is Associated with Improved Survival: A SEER-Medicare Analysis.

Authors:  Diamantis I Tsilimigras; J Madison Hyer; Anghela Z Paredes; Aslam Ejaz; Jordan M Cloyd; Joal D Beane; Mary Dillhoff; Allan Tsung; Timothy M Pawlik
Journal:  J Gastrointest Surg       Date:  2021-01-05       Impact factor: 3.452

2.  Outcomes of Pancreaticoduodenectomy for Pancreatic Neuroendocrine Tumors: Are Combined Procedures Justified?

Authors:  Cornelius A Thiels; John R Bergquist; Danuel V Laan; Kristopher P Croome; Rory L Smoot; David M Nagorney; Geoffrey B Thompson; Michael L Kendrick; Michael B Farnell; Mark J Truty
Journal:  J Gastrointest Surg       Date:  2016-02-29       Impact factor: 3.452

3.  Contrast-enhanced MDCT in patients with pancreatic neuroendocrine tumours: correlation with histological findings and diagnostic performance in differentiation between tumour grades.

Authors:  E Belousova; G Karmazanovsky; A Kriger; D Kalinin; L Mannelli; A Glotov; N Karelskaya; O Paklina; A Kaldarov
Journal:  Clin Radiol       Date:  2016-11-24       Impact factor: 2.350

Review 4.  [Surgical strategies for small sporadic neuroendocrine pancreatic tumors].

Authors:  K Holzer
Journal:  Chirurg       Date:  2018-06       Impact factor: 0.955

5.  Limitations of patient-associated co-morbidity model in predicting postoperative morbidity and mortality in pancreatic operations.

Authors:  Rupen Shah; Vic Velanovich; Zeeshan Syed; Andrew Swartz; Ilan Rubinfeld
Journal:  J Gastrointest Surg       Date:  2012-03-14       Impact factor: 3.452

6.  Palliative resection of the primary tumor in 442 metastasized neuroendocrine tumors of the pancreas: a population-based, propensity score-matched survival analysis.

Authors:  Felix J Hüttner; Lutz Schneider; Ignazio Tarantino; Rene Warschkow; Bruno M Schmied; Thilo Hackert; Markus K Diener; Markus W Büchler; Alexis Ulrich
Journal:  Langenbecks Arch Surg       Date:  2015-07-22       Impact factor: 3.445

7.  Predicting Progression, Recurrence, and Survival in Pancreatic Neuroendocrine Tumors: A Single Center Analysis of 174 Patients.

Authors:  Sara Krogh; Henning Grønbæk; Anders Riegels Knudsen; Peter Kissmeyer-Nielsen; Nynne Emilie Hummelshøj; Gitte Dam
Journal:  Front Endocrinol (Lausanne)       Date:  2022-06-28       Impact factor: 6.055

8.  Proposed thresholds for pancreatic tissue volume for safe intraportal islet autotransplantation after total pancreatectomy.

Authors:  J J Wilhelm; M D Bellin; T B Dunn; A N Balamurugan; T L Pruett; D M Radosevich; S Chinnakotla; S J Schwarzenberg; M L Freeman; B J Hering; D E R Sutherland; G J Beilman
Journal:  Am J Transplant       Date:  2013-10-21       Impact factor: 8.086

9.  Endoscopic ultrasound (EUS)-guided fiducial placement allows localization of small neuroendocrine tumors during parenchymal-sparing pancreatic surgery.

Authors:  Joanna K Law; Vikesh K Singh; Mouen A Khashab; Ralph H Hruban; Marcia Irene Canto; Eun Ji Shin; Payal Saxena; Matthew J Weiss; Timothy M Pawlik; Christopher L Wolfgang; Anne Marie Lennon
Journal:  Surg Endosc       Date:  2013-04-30       Impact factor: 4.584

10.  Pancreatic neuroendocrine tumor in a child of 3.5 years old.

Authors:  Shirin Sayyahfar; Seyed Javad Nassiri; Mitra Mehrazma; Mahnaz Sadeghian
Journal:  World J Pediatr       Date:  2014-06-28       Impact factor: 2.764

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.